CytoMed (NASDAQ: GDTC) stock is down 33% over the last 24 hours. GDTC stock fell in a mixture of real trading time, the aftermarket and now this morning. The reason for the decline is simply that it ...

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia ...

CytoMed (NASDAQ: GDTC) stock is up 100%. The rise in GDTC stock seems to be coming from the award of a patent. This is a very silly idea, quite ridiculous. Of course, it's just great for those who ...

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest announcement is out from ...

CytoMed Therapeutics is developing next-generation CAR-T cell therapies from γδ T cells for multiple solid tumor indications. The use of γδ T cells allows CytoMed to generate allogeneic, off-the-shelf ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

GDTC is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of GDTC shares has increased $0.23 since the market last closed. This is a 27.07% ...